When you linking your Twitter Account Market Wire News Trending Stocks news and your Portfolio Stocks News will automatically tweet from your Twitter account.
Be alerted of any news about your stocks and see what other stocks are trending.
MYOK - MyoKardia's mavacamten successful in late-stage study in inherited heart disorder
MyoKardia Inc.
MyoKardia (NASDAQ:MYOK) announces positive results from a Phase 3 clinical trial, EXPLORER-HCM, evaluating lead drug mavacamten in patients with symptomatic obstructive hypertrophic cardiomyopathy (HCM), an inherited disorder characterized by abnormal thickening of heart muscle leading to compromised cardiac function.
More news on: MyoKardia, Inc., Healthcare stocks news, Stocks on the move,